Brint S F, Cheetham J K, DeGryse R, Abel M L, Thompson V M, Rosenthal A
Eye Surgery Center of Louisiana, New Orleans, USA.
J Cataract Refract Surg. 1999 Jan;25(1):41-9. doi: 10.1016/s0886-3350(99)80009-1.
To investigate the efficacy and safety of nonpreserved ketorolac tromethamine 0.5% ophthalmic solution in relieving pain following radial keratotomy (RK).
Multicenter clinical trial.
Topical ketorolac was compared with its vehicle in a double-masked, randomized, parallel-group study involving 170 RK patients. Patients were treated with nonpreserved ketorolac 0.5% ophthalmic solution or the vehicle 4 times daily beginning immediately after surgery and continuing for 3 days or until they no longer had ocular pain.
At several intervals, patients treated with ketorolac reported significantly greater pain relief and less pain intensity than patients treated with the vehicle. The time required for patients to first report "complete relief" or "no pain" was shorter in the ketorolac than in the vehicle group (P < or = .006). Patients in the ketorolac group used less escape medication (acetaminophen) (P < or = .001) and had fewer sleep difficulties (P < or = .031), fewer symptoms of ocular discomfort (P < or = .028), and less difficulty performing activities of daily living (P = .048). Patients treated with ketorolac experienced the same low rate of treatment-related adverse events as those treated with the vehicle and exhibited the same improvement in visual acuity and manifest refraction.
Nonpreserved ketorolac tromethamine 0.5% ophthalmic solution was significantly more effective than, and as safe as, the vehicle in alleviating the postoperative pain associated with RK. This resulted in significant improvements in patient quality of life and less need for oral analgesics, suggesting that topical ketorolac is an appropriate treatment option for ocular pain following RK.
探讨0.5%非保存型酮咯酸氨丁三醇眼药水缓解放射状角膜切开术(RK)后疼痛的疗效和安全性。
多中心临床试验。
在一项双盲、随机、平行组研究中,将局部使用的酮咯酸与其赋形剂进行比较,该研究纳入了170例RK患者。患者于术后立即开始每天4次使用0.5%非保存型酮咯酸氨丁三醇眼药水或赋形剂,持续3天或直至不再有眼部疼痛。
在几个时间点,使用酮咯酸治疗的患者报告的疼痛缓解程度明显大于使用赋形剂治疗的患者,且疼痛强度更低。与赋形剂组相比,酮咯酸组患者首次报告“完全缓解”或“无疼痛”所需的时间更短(P≤0.006)。酮咯酸组患者使用的解救药物(对乙酰氨基酚)更少(P≤0.001),睡眠困难更少(P≤0.031),眼部不适症状更少(P≤0.028),日常生活活动困难更少(P = 0.048)。使用酮咯酸治疗的患者与使用赋形剂治疗的患者发生与治疗相关不良事件的发生率相同,且视力和明显验光的改善情况相同。
0.5%非保存型酮咯酸氨丁三醇眼药水在缓解RK相关术后疼痛方面明显比赋形剂更有效且同样安全。这显著改善了患者的生活质量,减少了口服镇痛药的需求,表明局部使用酮咯酸是RK后眼部疼痛的合适治疗选择。